DRRX DURECT Corporation Stock Quote

DRRX [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-0.07	Insider Own	1.42%	Shs Outstand	224.49M	Perf Week	-3.98%
Market Cap	401.95M	Forward P/E	-	EPS next Y	-0.27	Insider Trans	0.00%	Shs Float	206.09M	Perf Month	-23.53%
Income	-14.30M	PEG	-	EPS next Q	-0.04	Inst Own	49.50%	Short Float	4.43%	Perf Quarter	-23.18%
Sales	30.10M	P/S	13.35	EPS this Y	40.10%	Inst Trans	0.73%	Short Ratio	3.98	Perf Half Y	-6.63%
Book/sh	0.20	P/B	8.45	EPS next Y	-36.80%	ROA	-0.80%	Target Price	-	Perf Year	-8.15%
Cash/sh	0.17	P/C	9.88	EPS next 5Y	15.00%	ROE	-1.90%	52W Range	1.52 - 2.96	Perf YTD	-18.36%
Dividend	-	P/FCF	-	EPS past 5Y	17.80%	ROI	-20.70%	52W High	-42.91%	Beta	1.37
Dividend %	-	Quick Ratio	5.70	Sales past 5Y	9.50%	Gross Margin	95.30%	52W Low	11.18%	ATR	0.12
Employees	81	Current Ratio	5.90	Sales Q/Q	385.50%	Oper. Margin	-41.90%	RSI (14)	37.63	Volatility	7.30% 6.32%
Optionable	Yes	Debt/Eq	0.52	EPS Q/Q	-176.60%	Profit Margin	-1.90%	Rel Volume	0.40	Prev Close	1.60
Shortable	Yes	LT Debt/Eq	0.50	Earnings	Mar 04 AMC	Payout	-	Avg Volume	2.29M	Price	1.69
Recom	1.80	SMA20	-8.97%	SMA50	-21.31%	SMA200	-16.74%	Volume	916,667	Change	5.63%

Oct-30-20

Initiated

Chardan Capital Markets

Buy

Oct-12-20

Initiated

ROTH Capital

Buy

Jul-31-20

Initiated

Oppenheimer

Outperform

Jan-31-20

Initiated

B. Riley FBR

Buy

Nov-18-19

Resumed

Cantor Fitzgerald

Overweight

Sep-06-19

Initiated

Cantor Fitzgerald

Overweight

Mar-06-18

Upgrade

H.C. Wainwright

Neutral → Buy

$3.50

Oct-20-17

Reiterated

Laidlaw

Buy

$3 → $2

Oct-20-17

Downgrade

Stifel

Buy → Hold

$3 → $0.90

Oct-20-17

Downgrade

H.C. Wainwright

Buy → Neutral

Jul-12-17

Upgrade

Stifel

Hold → Buy

$1.25 → $3

Feb-28-17

Resumed

H.C. Wainwright

Buy

Apr-25-16

Initiated

Rodman & Renshaw

Buy

May-01-15

Reiterated

Stifel

Buy

$1.50 → $2.50

May-01-15

Reiterated

Cantor Fitzgerald

Buy

$2.50 → $3

Mar-25-13

Initiated

Stifel

Buy

Nov-01-12

Downgrade

C.K. Cooper

Buy → Hold

Aug-17-12

Initiated

C.K. Cooper

Buy

Jun-23-09

Initiated

Caris & Company

Buy

Mar-26-09

Initiated

Wedbush Morgan

Hold

Mar-09-21 09:00AM	DURECT Corporation Announces Publication of DUR-928's Mechanism of Action PR Newswire
Mar-04-21 05:31PM	Durect: Q4 Earnings Insights Benzinga -6.02%
05:25PM	Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates Zacks
02:30PM	DURECT Corp. to Host Earnings Call ACCESSWIRE
Mar-03-21 06:02PM	DURECT Corporation to Participate in Three Investor Conferences in March 2021 PR Newswire -6.49%
Feb-04-21 09:18AM	DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common Stock PR Newswire -15.68%
Feb-03-21 04:01PM	DURECT Corporation Announces Proposed Offering of Common Stock PR Newswire +15.73%
Feb-02-21 08:28AM	Durect stock soars 34% after it gets FDA approval for surgical pain treatment MarketWatch +18.10%
08:01AM	DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression PR Newswire
Jan-25-21 08:30AM	DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis PR Newswire +6.22%
Jan-05-21 08:30AM	DURECT Corporation Appoints Two New Board Members PR Newswire
Jan-04-21 08:30AM	DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million PR Newswire
Dec-21-20 08:30AM	DURECT Corporation to Participate in Investor Conferences in January 2021 PR Newswire
Dec-16-20 08:30AM	DURECT Corporation Announces DUR-928 Granted FDA Fast Track Designation for Treatment of Alcoholic Hepatitis PR Newswire
Dec-09-20 01:33PM	Is DRRX A Good Stock To Buy Now? Insider Monkey
Dec-07-20 11:15AM	DURECT Corporation to Sell its LACTEL® Absorbable Polymer Product Line to Evonik for $15 Million PR Newswire
Nov-13-20 09:00AM	DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience 2020 PR Newswire
Nov-10-20 08:30AM	DURECT Corporation to Host Webinar on the Treatment of Alcoholic Hepatitis Featuring Chief Medical Officer Dr. Norman Sussman PR Newswire
Nov-02-20 11:31PM	Durect Corp (DRRX) Q3 2020 Earnings Call Transcript Motley Fool
06:15PM	Durect (DRRX) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:05PM	DURECT Corporation Announces Third Quarter 2020 Financial Results and Update of Programs PR Newswire
04:02PM	DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer PR Newswire
02:30PM	DURECT Corp. to Host Earnings Call ACCESSWIRE
07:35AM	Forget Bargain Hunting: Play 5 Stocks With Rising P/E Zacks
Oct-27-20 08:30AM	DURECT Corporation to Announce Third Quarter 2020 Financial Results and Provide Business Update on November 02, 2020 PR Newswire
Oct-26-20 04:30PM	DURECT Corporation to Participate in the ROTH Capital Partners Healthcare Event "Covid-19 Therapeutics in Development" PR Newswire
12:31PM	Durect (DRRX) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Oct-05-20 08:30AM	DURECT Corporation to Present Additional Safety and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience 2020 PR Newswire
Sep-30-20 04:53PM	DURECT Corporation to Participate in Fireside Chat at H.C. Wainwright 4th Annual NASH Investor Conference PR Newswire
Sep-23-20 08:30AM	DURECT Corporation Announces First Patient Dosed in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury PR Newswire
Sep-22-20 08:30AM	DURECT Corporation Announces Design of Phase 2b AH Study (AHFIRM) PR Newswire
Sep-10-20 08:30AM	DURECT Corporation to Participate in September Virtual Investor Conferences PR Newswire
Aug-27-20 08:30AM	DURECT Corporation Announces Presentation of Phase 2a Pharmacokinetic Data of DUR-928 in Alcoholic Hepatitis at Digital International Liver Congress (EASL) PR Newswire -5.03%
Aug-26-20 04:30PM	DURECT Corporation Fireside Chat hosted by Ellie Merle of Cantor Fitzgerald PR Newswire
Aug-05-20 03:31PM	Oppenheimer: These 3 Strong Buy Stocks Could Double, If Not More TipRanks
08:30AM	DURECT to Present at the BTIG Biotechnology Conference 2020 PR Newswire
Aug-04-20 01:00AM	Durect Corp (DRRX) Q2 2020 Earnings Call Transcript Motley Fool
Aug-03-20 06:35PM	Durect (DRRX) Q2 Earnings and Revenues Beat Estimates Zacks +19.64%
04:05PM	DURECT Corporation Announces Second Quarter 2020 Financial Results and Update of Programs PR Newswire
Jul-28-20 08:30AM	DURECT Corporation to Announce Second Quarter 2020 Financial Results and Provide Business Update on August 03 PR Newswire
Jul-07-20 07:35AM	Is It Too Late to Buy These 3 Pharmaceutical Stocks? Motley Fool
Jul-01-20 08:30AM	DURECT Corporation Announces Initiation of Patient Recruitment in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury PR Newswire
Jun-29-20 09:00AM	U.S. FDA seeks more data on Heron Therapeutics' non-opioid painkiller Reuters
08:30AM	DURECT Corporation Joins the Russell 3000® Index PR Newswire
Jun-26-20 05:15PM	Gilead Terminates License Agreement for Long-Acting Injectable HIV Investigational Product PR Newswire -11.23%
10:37AM	DURECT Corporation (DRRX): Hedge Funds Are Nibbling Insider Monkey
Jun-11-20 02:45PM	Top Pharmaceutical Stocks for Q3 2020 Investopedia -8.15%
May-28-20 09:00AM	DURECT to Present at the Jefferies 2020 Virtual Health Care Conference PR Newswire -8.46%
May-26-20 08:30AM	DURECT Corporation Announces Positive Topline Data from Phase 1b Study of DUR-928 in NASH PR Newswire +7.69%
May-20-20 10:04AM	Billionaire Jim Simons Pulls the Trigger on These 3 Healthcare Stocks TipRanks
May-12-20 03:00PM	Durect Corp (DRRX) Q1 2020 Earnings Call Transcript Motley Fool +21.33%
02:20PM	Here's Why Shares of Durect Jumped Higher Today Motley Fool
May-11-20 06:55PM	Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:05PM	DURECT Corporation Announces First Quarter 2020 Financial Results and Update of Programs PR Newswire
May-04-20 05:00PM	DURECT Corporation to Announce First Quarter 2020 Financial Results and Provide Business Update on May 11 PR Newswire
Apr-28-20 12:33PM	Durect (DRRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Mar-24-20 04:18PM	Edited Transcript of DRRX earnings conference call or presentation 3-Mar-20 9:30pm GMT Thomson Reuters StreetEvents +10.24%
Mar-03-20 04:05PM	DURECT Corporation Announces Fourth Quarter and Full Year 2019 Financial Results and Update of Programs PR Newswire -9.95%
Feb-26-20 07:30AM	DURECT Corporation to Announce 2019 Financial Results on March 3 PR Newswire
Feb-10-20 08:05AM	3 Strong Buy Healthcare Stocks With Triple-Digit Upside TipRanks +11.32%
Jan-31-20 11:14AM	5 Stocks Under $5 With Colossal Growth Prospects InvestorPlace
Jan-17-20 08:19AM	UPDATE: Durect stock slides after FDA committee ends meeting with split vote on post-surgical pain treatment MarketWatch
08:07AM	The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares Benzinga
06:45AM	DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR® PR Newswire
Jan-16-20 02:38PM	U.S. FDA panel split over approval of Durect's non-opioid painkiller Reuters
07:24AM	Biopharma Durect shares halted ahead of FDA committee meeting on post-surgical pain treatment MarketWatch
07:05AM	DURECT Corporation Trading Halted Today; FDA Advisory Committee to Discuss POSIMIR® (bupivacaine extended-release solution) for Post-Surgical Analgesia PR Newswire
Jan-02-20 05:28PM	Drug developer dips on failed psoriasis trial American City Business Journals -31.18%
10:08AM	Durect's stock tumbles after failed psoriasis trial MarketWatch
09:00AM	DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis PR Newswire
Dec-30-19 09:24AM	3 Healthcare Stocks With Huge FDA Decisions in January TipRanks +8.28%
Dec-29-19 09:40PM	Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-19-19 05:02PM	Hedge Funds Had Impeccable Timing Buying DURECT Corporation (DRRX) Insider Monkey +6.10%
Dec-05-19 03:21PM	Edited Transcript of DRRX earnings conference call or presentation 4-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-15-19 08:00AM	DURECT to Present at the Stifel 2019 Health Care Conference PR Newswire
Nov-12-19 08:45AM	DURECT Corporation Announces Positive Results from the Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis Patients in a Late-Breaking Presentation at The Liver Meeting® PR Newswire
Nov-06-19 05:47PM	DURECT to Host Key Opinion Leader Call on DUR-928 Phase 2a Alcoholic Hepatitis Study Results PR Newswire
Nov-04-19 04:05PM	DURECT Corporation Announces Third Quarter 2019 Financial Results and Update of Programs PR Newswire
Oct-30-19 08:00AM	DURECT Corporation to Announce Third Quarter 2019 Financial Results and Provide Business Update on November 4 PR Newswire
Oct-21-19 10:12AM	DURECT Announces DUR-928 Phase 2a Alcoholic Hepatitis Study Results Selected for Late-Breaking Oral Presentation at The Liver Meeting® 2019 PR Newswire
Oct-18-19 10:23AM	These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year American City Business Journals
Oct-17-19 04:05PM	DURECT to Present at Two Upcoming NASH Investor Conferences PR Newswire
Oct-07-19 08:00AM	DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Phase 1b DUR-928 Clinical Trial in NASH PR Newswire
Oct-02-19 08:00AM	DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR® for the Treatment of Post-Surgical Pain PR Newswire +6.51%
Sep-26-19 08:00AM	DURECT to Present at the 2019 Cantor Fitzgerald Global Health Care Conference PR Newswire
Sep-18-19 07:39AM	The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts Benzinga
Sep-17-19 08:00AM	DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis PR Newswire +8.57%
Sep-09-19 09:29AM	DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Utilizing DURECT's SABER® Technology PR Newswire
Sep-07-19 12:19PM	3 Biotech Stocks That Could Double Your Money Motley Fool
Sep-06-19 12:24PM	Why Durect Stock Is Up Today Motley Fool +7.23%
Sep-04-19 08:00AM	DURECT to Present at the 21st Annual Rodman and Renshaw Global Investment Conference Sponsored by H.C. Wainwright PR Newswire
Aug-29-19 04:44PM	Edited Transcript of DRRX earnings conference call or presentation 1-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-20-19 10:00AM	DRRX: Gilead Agreement, Near-Term Value-Inflection Opportunities Make DRRX Particularly Attractive at Current Valuation Zacks Small Cap Research
Aug-01-19 04:05PM	DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs PR Newswire
Jul-29-19 10:08AM	Health Care Digest: Kilroy's Oyster Point mystery, helping researchers ditch spreadsheets and more American City Business Journals
Jul-25-19 04:30PM	DURECT Corporation to Announce Second Quarter 2019 Financial Results on August 1 PR Newswire
Jul-22-19 08:00AM	DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product PR Newswire +33.64%
Jul-17-19 08:00AM	DURECT Announces that the FDA Agreed to File the Full Response to the POSIMIR® Complete Response Letter as a Complete Class 2 Resubmission PR Newswire
Jun-28-19 09:15AM	DRRX: Favorable FDA Decision on POSIMIR Would Likely Mean Significant Upside to Our Model Zacks Small Cap Research
Jun-27-19 08:30AM	DURECT Announces Submission to FDA of a Full Response to the POSIMIR® Complete Response Letter PR Newswire

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bleichroeder LP	10% Owner	Sep 01	Sale	1.68	250,000	420,000	26,414,656	Sep 02 04:25 PM
Joice Judy R	Sr. VP Operations & Corp QA	Jun 03	Option Exercise	0.78	57,820	45,100	67,611	Jun 05 08:33 PM
Joice Judy R	Sr. VP Operations & Corp QA	Jun 03	Sale	2.45	57,820	141,763	32,747	Jun 05 08:33 PM
Bleichroeder LP	10% Owner	May 26	Sale	2.50	39,388	98,525	26,664,656	May 28 06:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience